Related Experiment Video
Updated: Aug 10, 2025

Murine Corneal Transplantation: A Model to Study the Most Common Form of Solid Organ Transplantation
Published on: November 17, 2014
Recent advances in ocular graft-versus-host disease
Xianjing Cheng1,2, Ruihao Huang1, Shiqin Huang1
1Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burns and Combined Injury, Army Medical University, Chongqing, China.
Ocular graft-versus-host-disease (GVHD) after stem cell transplant impacts vision and quality of life. This review details its mechanisms, biomarkers, and novel treatments for better ocular GVHD management.
Area of Science:
- Ophthalmology
- Hematology
- Immunology
Background:
- Ocular graft-versus-host-disease (GVHD) is a common complication following allogeneic hematopoietic stem cell transplantation.
- It significantly impairs visual function and quality of life for patients.
- Current diagnostic and therapeutic approaches are challenging due to a lack of unified international criteria.
Purpose of the Study:
- To comprehensively review the pathogenesis of ocular GVHD.
- To summarize the current understanding of tear biomarkers associated with ocular GVHD.
- To discuss novel therapeutic strategies for ocular GVHD.
Main Methods:
- Literature review focusing on ocular GVHD pathogenesis.
- Analysis of studies on tear biomarkers in ocular GVHD.
- Exploration of emerging treatment modalities.
Main Results:
- Detailed summary of the complex pathogenic mechanisms underlying ocular GVHD.
- Identification of key tear biomarkers relevant to ocular GVHD diagnosis and monitoring.
- Overview of novel therapies targeting specific pathogenic pathways.
Conclusions:
- Understanding the pathogenesis is crucial for effective ocular GVHD management.
- Tear biomarkers offer potential for improved diagnosis and monitoring.
- Novel therapies hold promise for enhancing treatment outcomes in ocular GVHD.
More Related Videos
10:14Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
Published on: May 26, 2023
10:24Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment